SectorBiotechnology Ⅲ
Established Date16/12/2022
Listing Date05/08/2026
ExchangeNASDAQ Stock Exchange
Full-time Employees44
Fiscal Year Ends31/12
Security TypeCommon stock
Office address1091 Industrial Road
Suite 310
San Carlos
California 94070
BusinessDevelops biotherapeutics for immune-mediated diseases.
IntroductionAttovia Therapeutics, Inc., was incorporated in Delaware on December 16, 2022. The company is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline drug candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform, which is licensed by Alamar Biosciences, Inc.